NCT00052195View on ClinicalTrials.gov

Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,975

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

December 31, 2008

Study Completion Date

May 31, 2009

Conditions
TuberculosisHIV Infections
Interventions
BIOLOGICAL

SRL-172

5 doses of 0.1mL vaccine or placebo given intradermally over 12-months

Trial Locations (1)

Unknown

Muhimbili University College of Health Sciences, Dar es Salaam

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00052195 - Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People | Biotech Hunter | Biotech Hunter